Thursday November 26 2009 | Biotechnology feed | All feeds
|
|
Transport Pharmaceuticals, Inc.
Download detailed PDF Members: Transport Pharmaceuticals, Inc. is developing a proprietary iontophoretic drug delivery technology applicable to multiple dermatological diseases, with an initial focus on herpes labialis, or cold sores. The company's lead product enables the delivery of high doses of acyclovir, an approved cold sore treatment, directly to impacted skin areas, addressing a primary barrier to effective treatment of herpes labialis. The company operates under the management of neXus therapeutics, inc.NeXus is a biopharmaceutical management company that employs an "essential product development" paradigm to enhance the development process of early stage drugs and combination products. NeXus has an exclusive agreement with Transport to manage the company's business operations and product design and development.
This page has been viewed 414 times since April 2007, the link to the organisation's website has been followed 63 times Recent Search Terms used to find this page: transport pharmaceuticals inc.2009 | transport pharmaceuticals 2009 | transport pharmaceuticals 2009 | transport pharmaceuticals inc news | transport pharmaceuticals home page | Transport Pharmaceuticals | transport pharma | transport pharma | transport pharma | transport pharmaceuticals | . Search for more companies in Framingham Search for more companies in Massachusetts This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Transport Pharmaceuticals, Inc. | ||||||||||||||||||||||||||||||||||
|